开云app官网登录入口网页版-官方正版

#OX40#

8篇内容 | 1112人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2182809, encodeId=fd4f2182809d3, content=<a href='/topic/show?id=d8dbe130197' target=_blank style='color:#2F92EE;'>#癌症#</a> <a href='/topic/show?id=dd291356302' target=_blank style='color:#2F92EE;'>#OX40L#</a> <a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a>, objectTitle=OX40/OX40L：癌症及自免疫明星靶点, objectType=article, longId=810084, objectId=b8f4810084e2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240118/25c76e5e7daf4e4a97dc93f3d168dbcd.jpg, objectUrl=/article/show_article.do?id=b8f4810084e2, replyNumber=0, likeNumber=52, createdTime=2024-01-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=b8f4810084e2, moduleTitle=OX40/OX40L：癌症及自免疫明星靶点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b8f4810084e2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2163062, encodeId=6dfe2163062b2, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a><a href='/topic/show?id=07a69996557' target=_blank style='color:#2F92EE;'>#靶点#</a>可能成为<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>新的明星靶点! <a href='/topic/show?id=597010e014a8' target=_blank style='color:#2F92EE;'>#OX40L单抗#</a><a href='/topic/show?id=10c010e015ac' target=_blank style='color:#2F92EE;'>#amlitelimab#</a>的临床试验IIb达到主要终点。此前<a href='/topic/show?id=f68a10e01698' target=_blank style='color:#2F92EE;'>#Rocatinlimab#</a>同样效果不俗。使得特应性皮炎，从<a href='/topic/show?id=0377963352' target=_blank style='color:#2F92EE;'>#IL-13#</a>， <a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>， <a href='/topic/show?id=51f09653ba' target=_blank style='color:#2F92EE;'>#IL-21#</a>等不同的靶点，进一步拓展至OX40L，未来可能对于单一治疗效果不好的病人，可以多药联用，有望取得更好的效果。另外，还有必要开发针对婴幼儿的特应性皮炎的治疗，这是临床刚需。 <a href='/topic/show?id=e9846644229' target=_blank style='color:#2F92EE;'>#湿疹#</a>, objectTitle=OX40靶点可能成为特应性皮炎新的明星靶点! OX40L单抗amlitelimab的临床试验IIb达到主要终点, objectType=article, longId=796440, objectId=8e91e9644062, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230930/2b4e70e4d38248488b6c4dfee3c353b8.jpg, objectUrl=/article/show_article.do?id=8e91e9644062, replyNumber=0, likeNumber=111, createdTime=2023-10-16, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8e91e9644062, moduleTitle=OX40靶点可能成为特应性皮炎新的明星靶点! OX40L单抗amlitelimab的临床试验IIb达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8e91e9644062)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2029715, encodeId=77ce2029e1530, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a>, objectTitle=Front Cell Dev Biol：HSA_CIRC_0000652通过激活巨噬细胞和增强OX40/OX40L相互作用而加重强直性脊柱炎的炎症反应, objectType=article, longId=293935, objectId=cd2229393548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd2229393548, replyNumber=0, likeNumber=86, createdTime=2022-02-23, rootId=0, userName=ms3830150583600765, userId=dd282500126, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd2229393548, moduleTitle=Front Cell Dev Biol：HSA_CIRC_0000652通过激活巨噬细胞和增强OX40/OX40L相互作用而加重强直性脊柱炎的炎症反应, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cd2229393548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029714, encodeId=e05a2029e142d, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a>, objectTitle=Clin Cancer Res：OX40激动剂Ivuxolimab在局部晚期或转移性癌症患者中的应用, objectType=article, longId=220548, objectId=8b2c22054893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b2c22054893, replyNumber=0, likeNumber=55, createdTime=2022-01-04, rootId=0, userName=ms3830150583600765, userId=dd282500126, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b2c22054893, moduleTitle=Clin Cancer Res：OX40激动剂Ivuxolimab在局部晚期或转移性癌症患者中的应用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8b2c22054893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029713, encodeId=a80f2029e13df, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a>, objectTitle=Nat Commun：新辅助抗OX40疗法（MEDI6469）治疗头颈部鳞状细胞癌患者的临床研究, objectType=article, longId=207670, objectId=aec820e67021, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aec820e67021, replyNumber=0, likeNumber=64, createdTime=2021-12-15, rootId=0, userName=ms3830150583600765, userId=dd282500126, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aec820e67021, moduleTitle=Nat Commun：新辅助抗OX40疗法（MEDI6469）治疗头颈部鳞状细胞癌患者的临床研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aec820e67021)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029712, encodeId=4f5d2029e121c, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a>, objectTitle=Journal for ImmunoTherapy of Cancer：CTLA-4及OX40双特异性抗体ATOR-1015的临床前数据, objectType=article, longId=164218, objectId=ac0f164218bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac0f164218bb, replyNumber=0, likeNumber=64, createdTime=2019-11-20, rootId=0, userName=ms3830150583600765, userId=dd282500126, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac0f164218bb, moduleTitle=Journal for ImmunoTherapy of Cancer：CTLA-4及OX40双特异性抗体ATOR-1015的临床前数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ac0f164218bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029711, encodeId=13db2029e11e5, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a>, objectTitle=Glenmark Pharmaceuticals在美国皮肤病学会年会上介绍GBR 830（抗OX40单抗）的2a期临床数据, objectType=article, longId=161549, objectId=c3c3161549aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3c3161549aa, replyNumber=0, likeNumber=63, createdTime=2019-09-18, rootId=0, userName=ms3830150583600765, userId=dd282500126, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3c3161549aa, moduleTitle=Glenmark Pharmaceuticals在美国皮肤病学会年会上介绍GBR 830（抗OX40单抗）的2a期临床数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c3c3161549aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029710, encodeId=6c3a2029e10cb, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a>, objectTitle=Allergol Immunopathol (Madr)：过敏性鼻炎中，B细胞OX40配体与CD4+ T细胞血清总lgE和IL-4水平相关性分析, objectType=article, longId=154377, objectId=19e41543e7e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19e41543e7e7, replyNumber=0, likeNumber=82, createdTime=2019-07-25, rootId=0, userName=ms3830150583600765, userId=dd282500126, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19e41543e7e7, moduleTitle=Allergol Immunopathol (Madr)：过敏性鼻炎中，B细胞OX40配体与CD4+ T细胞血清总lgE和IL-4水平相关性分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=19e41543e7e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029709, encodeId=08a62029e09f8, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a>, objectTitle=ANN RHEUM DIS：B细胞OX40L支持滤泡辅助性T细胞发育并导致SLE发病, objectType=article, longId=109183, objectId=337910918316, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=337910918316, replyNumber=0, likeNumber=93, createdTime=2018-02-11, rootId=0, userName=ms3830150583600765, userId=dd282500126, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=337910918316, moduleTitle=ANN RHEUM DIS：B细胞OX40L支持滤泡辅助性T细胞发育并导致SLE发病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=337910918316)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

OX40

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#癌症# #OX40L# #OX40#

OX40/OX40L：癌症及自免疫明星靶点

2024-01-20发表于加利福尼亚

侠胆医心 (审核中...)

前往app查看评论内容

全文收起 #OX40##靶点#可能成为#特应性皮炎#新的明星靶点! #OX40L单抗##amlitelimab#的临床试验IIb达到主要终点。此前#Rocatinlimab#同样效果不俗。使得特应性皮炎，从#IL-13#， #IL-17#， #IL-21#等不同的靶点，进一步拓展至OX40L，未来可能对于单一治疗效果不好的病人，可以多药联用，有望取得更好的效果。另外，还有必要开发针对婴幼儿的特应性皮炎的治疗，这是临床刚需。 #湿疹#

OX40靶点可能成为特应性皮炎新的明星靶点! OX40L单抗amlitelimab的临床试验IIb达到主要终点

2023-10-16发表于上海

ms3830150583600765 (审核中...)

前往app查看评论内容

#OX40#

Front Cell Dev Biol：HSA_CIRC_0000652通过激活巨噬细胞和增强OX40/OX40L相互作用而加重强直性脊柱炎的炎症反应

2022-02-23

ms3830150583600765 (审核中...)

前往app查看评论内容

#OX40#

Clin Cancer Res：OX40激动剂Ivuxolimab在局部晚期或转移性癌症患者中的应用

2022-01-04

ms3830150583600765 (审核中...)

前往app查看评论内容

#OX40#

Nat Commun：新辅助抗OX40疗法（MEDI6469）治疗头颈部鳞状细胞癌患者的临床研究

2021-12-15

ms3830150583600765 (审核中...)

前往app查看评论内容

#OX40#

Journal for ImmunoTherapy of Cancer：CTLA-4及OX40双特异性抗体ATOR-1015的临床前数据

2019-11-20

ms3830150583600765 (审核中...)

前往app查看评论内容

#OX40#

Glenmark Pharmaceuticals在美国皮肤病学会年会上介绍GBR 830（抗OX40单抗）的2a期临床数据

2019-09-18

ms3830150583600765 (审核中...)

前往app查看评论内容

#OX40#

Allergol Immunopathol (Madr)：过敏性鼻炎中，B细胞OX40配体与CD4+ T细胞血清总lgE和IL-4水平相关性分析

2019-07-25

ms3830150583600765 (审核中...)

前往app查看评论内容

#OX40#

ANN RHEUM DIS：B细胞OX40L支持滤泡辅助性T细胞发育并导致SLE发病

2018-02-11

科室
- - 订阅+
  - 更多科室
工具
服务